A rescue approach in refractory diffuse large B-cell lymphoma with obinutuzumab-redirected cytokineinduced killer cells: a first-in-human case report

Francesca Elice; Roberta Sommaggio; Elisa Cappuzzello; Marcello Riva; Maria Chiara Tisi; Martina Bernardi; Angela Bozza; Daniela Catanzaro; Katia Chieregato; Anna Merlo; Ilaria Giaretta; Anna Dalla Pieta; Mauro Krampera; Carlo Visco; Livio Trentin; Andrea Visentin; Alberto Tosetto; Giuseppe Astori; Antonio Rosato

doi:10.3324/haematol.2023.284881

A rescue approach in refractory diffuse large B-cell lymphoma with obinutuzumab-redirected cytokineinduced killer cells: a first-in-human case report

Haematologica. 2024 Sep 1;109(9):3037-3041. doi: 10.3324/haematol.2023.284881.

Authors

Francesca Elice¹, Roberta Sommaggio², Elisa Cappuzzello³, Marcello Riva¹, Maria Chiara Tisi¹, Martina Bernardi⁴, Angela Bozza⁴, Daniela Catanzaro⁴, Katia Chieregato⁴, Anna Merlo⁴, Ilaria Giaretta¹, Anna Dalla Pieta⁵, Mauro Krampera⁶, Carlo Visco⁶, Livio Trentin⁷, Andrea Visentin⁷, Alberto Tosetto¹, Giuseppe Astori⁴, Antonio Rosato²

Affiliations

¹ Hematology, San Bortolo Hospital, Vicenza.
² Department of Surgery, Oncology and Gastroenterology, University of Padua, Padua, Italy; Veneto Institute of Oncology-IOV IRCCS, Padua.
³ Veneto Institute of Oncology-IOV IRCCS, Padua. [email protected].
⁴ Advanced Cellular Therapy Laboratory, Hematology, San Bortolo Hospital, Vicenza.
⁵ Department of Surgery, Oncology and Gastroenterology, University of Padua, Padua.
⁶ Hematology and Bone Marrow Transplant Unit, Section of Biomedicine of Innovation, Department of Engineering for Innovative Medicine, University of Verona, Verona.
⁷ Hematology Unit, Department of medicine, University of Padua, Padua.

No abstract available

Publication types

Case Reports
Letter

MeSH terms

Antibodies, Monoclonal, Humanized* / administration & dosage
Antibodies, Monoclonal, Humanized* / therapeutic use
Antineoplastic Agents, Immunological / administration & dosage
Antineoplastic Agents, Immunological / therapeutic use
Antineoplastic Combined Chemotherapy Protocols / therapeutic use
Drug Resistance, Neoplasm
Humans
Killer Cells, Natural / drug effects
Killer Cells, Natural / immunology
Lymphoma, Large B-Cell, Diffuse* / drug therapy
Lymphoma, Large B-Cell, Diffuse* / pathology
Lymphoma, Large B-Cell, Diffuse* / therapy
Male
Middle Aged
Treatment Outcome

Substances

Antibodies, Monoclonal, Humanized
obinutuzumab
Antineoplastic Agents, Immunological

Grants and funding

Funding: This study was supported by AIRC Foundation - IG 2018 - ID. 2135; AIRC Foundation under 5x1000 2019 - ID. 22759 program Veneto Institute of Oncology IOV - I.R.C.C.S -5x1000 fund; Ricerca Corrente 2024 to AR; AVILL-AIL - Associazione Italiana Leucemie, Associazione Vicentina per le Leucemie e i Linfomi - Bando Benvenuti.